CD58.md
... ...
@@ -7,7 +7,12 @@ link-citations: true
7 7
8 8
## Overview
9 9
10
-CD58, also known as lymphocyte function-associated antigen 3 (LFA-3), is crucial for immune recognition, facilitating interactions between tumor cells and cytotoxic T cells and natural killer (NK) cells. In DLBCL, mutations prevent the expression of CD58 on the cell surface, impairing the ability of T and NK cells to recognize and attack the tumor cells. This is often accompanied by mutations in the β2-Microglobulin gene, which further aids in immune evasion.<sup>1</sup>
10
+CD58, also known as lymphocyte function-associated antigen 3 (LFA-3), is crucial for immune recognition, facilitating interactions between tumor cells and cytotoxic T cells and natural killer (NK) cells.
11
+
12
+## Experimental Evidence
13
+
14
+In DLBCL, mutations prevent the expression of CD58 on the cell surface, impairing the ability of T and NK cells to recognize and attack the tumor cells.
15
+This is often accompanied by mutations in the β2-Microglobulin gene, which further aids in immune evasion.[@challa-malladiCombinedGeneticInactivationa]
11 16
12 17
## History
13 18
```mermaid
... ...
@@ -23,7 +28,7 @@ timeline
23 28
|Entity|Tier|Description |
24 29
|:------:|:----:|--------------------------------------|
25 30
|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@schneiderAlterationsCD58Gene2015a]|
26
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
31
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-EE |high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
27 32
28 33
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
29 34
DLBCL_genes.md
... ...
@@ -31,9 +31,9 @@ link-citations: true
31 31
|[BTK](BTK)|1|[Albuquerque et al](papers/albuquerqueEnhancingKnowledgeDiscovery2017a)[@albuquerqueEnhancingKnowledgeDiscovery2017a]|[@krysiakRecurrentSomaticMutations2017b]|
32 32
|[CARD11](CARD11)|1|[Lenz et al](papers/lenzOncogenicCARD11Mutations2008)[@lenzOncogenicCARD11Mutations2008]|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019; @yanBCRTLRSignaling2012a; @wuGeneticHeterogeneityPrimary2016]|
33 33
|[CCND3](CCND3)|1|[Morin et al](papers/morinFrequentMutationHistonemodifying2011)[@morinFrequentMutationHistonemodifying2011]|[@jalladesExomeSequencingIdentifies2017; @deschGenotypingCirculatingTumor2020; @richterRecurrentMutationID32012a]|
34
-|[CD58](CD58)|1|[Morin et al](papers/morinFrequentMutationHistonemodifying2011)[@morinFrequentMutationHistonemodifying2011]|[@schneiderAlterationsCD58Gene2015a]|
34
+|[CD58](CD58)|1-EE|[Morin et al](papers/morinFrequentMutationHistonemodifying2011)[@morinFrequentMutationHistonemodifying2011]|[@schneiderAlterationsCD58Gene2015a]|
35 35
|[CD70](CD70)|1|[Morin et al](papers/morinFrequentMutationHistonemodifying2011)[@morinFrequentMutationHistonemodifying2011]|[@russler-germainMutationsAssociatedProgression2023b]|
36
-|[CD79B](CD79B)|1|[Morin et al](papers/morinFrequentMutationHistonemodifying2011)[@morinFrequentMutationHistonemodifying2011]|[@paneaWholeGenomeLandscape2019]|
36
+|[CD79B](CD79B)|1-EE|[Morin et al](papers/morinFrequentMutationHistonemodifying2011)[@morinFrequentMutationHistonemodifying2011]|[@paneaWholeGenomeLandscape2019]|
37 37
|[CD83](CD83)|1|[Morin et al](papers/morinMutationalStructuralAnalysis2013)[@morinMutationalStructuralAnalysis2013]|[@paneaWholeGenomeLandscape2019; @dunsCharacterizationDLBCLPMBL2021b; @russler-germainMutationsAssociatedProgression2023b]|
38 38
|[CDKN2A](CDKN2A)|1|[Morin et al](papers/morinMutationalStructuralAnalysis2013)[@morinMutationalStructuralAnalysis2013]|[@spinaGeneticsNodalMarginal2016b; @grandeGenomewideDiscoverySomatic2019]|
39 39
|[CREBBP](CREBBP)|1-EE|[Pasqualucci et al](papers/pasqualucciInactivatingMutationsAcetyltransferase2011a)[@pasqualucciInactivatingMutationsAcetyltransferase2011a]|[@parryWholeExomeSequencing2013; @dunsCharacterizationDLBCLPMBL2021b; @loveGeneticLandscapeMutations2012]|
MEF2B.md
... ...
@@ -25,8 +25,8 @@ timeline
25 25
|Entity|Tier|Description |
26 26
|:------:|:----:|--------------------------------------|
27 27
|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
28
-|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
29
-|![FL](images/icons/FL_tier1.png) |1-a | aSHM target and high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
28
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-EE | high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
29
+|![FL](images/icons/FL_tier1.png) |1-EE | high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
30 30
31 31
32 32
## Mutation incidence in large patient cohorts (GAMBL reanalysis)